This article is more than 5 years old. Information may no longer be current.
Cardiology Today's top stories covered at the ACC Scientific Session
Click Here to Manage Email Alerts
The American College of Cardiology Scientific Session featured important late-breaking clinical trials and other material presented by some of the world’s leading cardiologists. Cardiology Today has compiled a list of the top studies, presentations and abstracts presented at the meeting this year.
Highlights from this year’s session include the EINSTEIN-CHOICE trial, the EBBINGHAUS trial, the FOURIER trial, the GIFT trial and much more.
EINSTEIN-CHOICE: Recurrent VTE lower with rivaroxaban vs. aspirin, without rise in bleeding
WASHINGTON — Patients with venous thromboembolism assigned 10 mg or 20 mg of rivaroxaban had lower risk for recurrence compared with those who used aspirin, with no difference in bleeding, according to new data from the EINSTEIN-CHOICE trial.
EBBINGHAUS: Evolocumab does not affect cognitive outcomes
WASHINGTON — The addition of evolocumab to statin therapy did not result in memory loss or other cognitive issues, according to results of the EBBINGHAUS study.
FOURIER: Reducing LDL to very low levels with evolocumab confers reduced risk for CV events
WASHINGTON — Reduction of LDL to a median of 30 mg/dL with the PCSK9 inhibitor evolocumab in patients with atherosclerotic CVD was associated with lowered risk for CV events, according to data from the FOURIER CV outcomes trial.
VIDEO: Real-world data show benefit of direct oral anticoagulants
WASHINGTON — In this Cardiology Today video perspective, Alpesh Amin, MD, professor and chairman of medicine at the University of California, Irvine, discusses two abstracts comparing direct oral anticoagulants to warfarin in real-world populations with nonvalvular atrial fibrillation presented here.
Debate: Necessity of ECG screenings in young athletes still uncertain
WASHINGTON — While ECG screenings in school-age athletes may be necessary to reduce risk for sudden cardiac death, there are questions that need to be answered about accuracy of diagnosis, two experts said in a debate here.
Closed-loop stimulation pacing program reduces syncope in SPAIN trial
WASHINGTON — A pacemaker delivering a closed-loop stimulation pacing program was associated with a sevenfold reduction in syncope, researchers reported.
Exercise helps decrease CV risk in women after breast cancer
WASHINGTON — Regular exercise before breast cancer diagnosis was associated with reductions in CV risk among women treated for breast cancer, according to a new report.
SGLT2 inhibitors may lower risk for HF in patients with type 2 diabetes
WASHINGTON — Sodium-glucose co-transporter 2 inhibitors were linked to decreased risk for hospitalization for HF and death, according to data from the CVD-REAL study.
DAPT with rivaroxaban or aspirin regimen confers similar outcomes in ACS
WASHINGTON — Among patients with ACS, substituting rivaroxaban for aspirin in dual antiplatelet therapy with a P2Y12 inhibitor did not lead to increased bleeding risk, but did not confer superior outcomes in the phase 2 GEMINI-ACS-1 trial.
GIFT: Genetics-based dosing improves warfarin safety
WASHINGTON — Pharmacogenetics-based warfarin dosing decreased adverse events compared with clinical-based dosing, investigators from the GIFT study reported.